González-Ortiz AM, Hernández-Téllez PA, Manzanares-Rodríguez L, Reyes-Gómez U, Chacón-Cruz E, Vargas-Mosso ME, Reyes-Hernández KL, Mercado-Díaz CU, Santamaría-Arza C, López-Cruz G, Reyes-Hernández MU, Matos-Alviso LJ, Miguel-Reyes A

Language: Spanish
References: 16
Page: 177-181
PDF size: 145.38 Kb.

ABSTRACT

Infections caused by Neisseria meningitidis such as meningitis and sepsis (meningococcemia) have a high risk of mortality (50-80% of cases) when antimicrobial is not received in a timely manner, and with treatment the risk of mortality can reach up to 20 % with possibility of sequelae in survivors.
This clinical case is a 3-month-old female without risk factors, who begins with an upper respiratory condition of 7 days of evolution. The blood culture developed Neisseria meningitidis classified as serogroup C, required amputation of necrotic fingers as a sequel, prophylaxis was implemented in family contacts and treating physicians, discharged for improvement 2 weeks later. Infections caused by Neisseria meningitidis are serious due to their rapid progression, high mortality and sequelae in survivors, such as the case presented.

REFERENCES

1. GIVEBPVac (Grupo Interinstitucional para la Vigilancia de Enfermedades Bacterianas Prevenibles por Vacunación). 2017.

2. . Report of the Committee on Infectious Diseases. 31st Edition. Red Book; 2018-2021.

3. World Health Organization. Control of epidemic meningococcal disease. WHO Practical guidelines. 2a Ed. [En línea]. http:// www.who.int/emc

4. Almeida-González L, Franco-Paredes C, Pérez-Luis F, Santos-Preciado, JI. Enfermedad por meningococo, Neisseria meningitidis: perspectiva epidemiológica, clínica y preventiva. Salud Pública de México. 2004; 46(5): 438-50.

5. Chacón CE, Sugerman DE, Ginsberg MM, Hopkins J, Hurtado MJ, López VJ, et al. Surveillance for invasive meningococcal disease in children. US-Mexico border 2005-2008. Emerg Infect Dis. 2011; 17: 543- 6.

6. Alerta Epidemiológica DGE/2010/13/Meningitis.

7. Chacón CE. An outbreak of serogroup C (ST-11) meningococcal disease in Tijuana, Mexico. The Adv Vaccines 2014; 2(3): 71-6

8. Medina-Reyes A, Díaz-Polanco B, Sandoval-Chávez D, Nodal-Hernández M, Ayala-Franco J. Neisseria meningitidis: caso clínico con afectación a múltiples órganos. Rev Med Inst Mex Seguro Soc. 2017; 55(3): 388-93.

9. Chacón-Cruz CE, Alvelais-Palacios JA, Lopatynsky- Reyes L, Rodríguez-Valencia A, Volker-Soberanes ML. Meningococcal Disease in Children: Eleven Years of Active Surveillance in a Mexican Hospital and the Need for Vaccination in the Tijuana Region. J Infec Dis Treat. 2017; 3(1): 1-4. [En línea]. http:// infectious-diseases-and-treatment.imedpub.com/current- issue.php

10. Patton ME, Stephens D, Moore K, MacNeil RJ. Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine Advisory Committee on Immunization Practices, 2016. MMWR. 2017; 66(19): 509-51.

11. Cohn AC, MacNeil JR, Clark TA, Ortega SI, Briere EZ, Meissner HC, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013; 62(RR-2): 1-28.

12. World Health Organization. Control of epidemic meningococcal disease. WHO Practical guidelines. 2a Ed. [En línea]. Disponible en: http://

13. American Academy of Pediatrics. Meningococcal infections. Kimberlin DW. Report of the Committee on Infectious Diseases. 31st Edition. Red Book: 2018-2021.

14. Burman C, Serra L, Nuttens C, Presa J, Balmer P, York L. Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination. Human vaccines & immunotherapeutics. 2019; 15(2): 459-69.

15. Kasper-DL, Fauci-AS. Harrison’s Infectious Diseases; 2010. US: McGraw-Hill: Medical Publishing.

16. Siqueira BR. Meningococcal disease, a clinical and epidemiological review. Asian Pacific Journal of Tropical Medicine. 2017; 10(11): 1019-29.